Abera Bioscience AB (NGM: ABERA)
Health Care · Biotechnology · SE
Skr8.26
+0.49% today · +4.6% 1Y
Abera Bioscience AB (NGM: ABERA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $17.88M.
Over the last twelve months the share price has gained 4.6%, trading between 5.15 and 10.05.
Tweenvest scores Abera Bioscience AB across four factors: quality 35/100, value 68/100. Its strongest factor is value.
ABERA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.88M
- Revenue (TTM)
- $938.50K
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.64
- 52-week high
- Skr10.05
- 52-week low
- Skr5.15
- Avg volume (3M)
- —
- Shares outstanding
- 20.50M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.08 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.95 | -0.20% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.37 | -0.26% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $545.46 | -0.39% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $826.01 | -0.30% |
| argenx SEENXTBR: ARGX | $63.06B | €872.20 | +0.93% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $144.03 | +3.70% |
Figures last refreshed Aug 18, 2026.